Record overview
Status and phase
Status: TERMINATED
Phase: PHASE1, PHASE2
Sponsor: National Cancer Institute (NCI)
Condition: Rhabdomyosarcoma, Rhabdomyosarcoma, Alveolar, Rhabdomyosarcoma, Embryonal
NCT03041701
Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar Rhabdomyosarcoma
Public trial-level signal summary for this oncology Phase 2 record.
Signal summary
Public flags
Status signal: Registry Stop Signal
Timeline signals: stale_update_signal
Results signal: Low Signal
Operational burden: rare_population_signal | strict_eligibility_signal
Stopped reason
Context when available
The pharmaceutical company discontinued availability of the drug and we were forced to close the study before phase II was completed. Only one participant was enrolled on phase II.